Skip to content

Read-only version: For security reasons, the Research Information System (FIS) has been temporarily replaced by this read-only version. All public content and full texts remain available; login, editing, submission and statistics are not available. Questions: fis@uni-bamberg.de

Home › Publications › Predictors of hypoglycemia avoidance in a randomized controlled rtCGM trial (HypoDE)

Publication

Predictors of hypoglycemia avoidance in a randomized controlled rtCGM trial (HypoDE)

Hermanns, Norbert; Heinemann, Lutz; Freckmann, Guido; u. a. (2018): Predictors of hypoglycemia avoidance in a randomized controlled rtCGM trial (HypoDE), in: Diabetes, Alexandria, Va: American Diabetes Association, Jg. 67, Nr. Suppl. 1, S. A79 (298-OR), doi: 10.2337/db18-298-OR.

Details

Faculty/Chair
Faculty/Professorship
Author
Heinemann, Lutz
Freckmann, Guido
Waldenmaier, Delia
Title of the Journal
Diabetes
ISSN
0012-1797
Corporate Body
American Diabetes Association
Publisher Information
American Diabetes Association : Alexandria, Va
Year of publication
2018
Volume
67
Issue
Suppl. 1
Language
English
Remark

Abstract:

The HypoDE study, a randomized multi-center trial, showed that rtCGM use reduces the number of low glucose events (<55 mg/dl for at least 20 minutes) per 28 days from 10.4 to 3.4 events compared to SMBG (13.5 to 13.2 events) in MDI-treated type 1 diabetic patients with hypoglycemia problems. In this post-hoc analysis, we analyzed which baseline variables predict successful reduction of low glucose events. The criterion was a reduction to 0 events or by 50% from baseline. In a block-wise, multivariate logistic regression, demographic and medical variables, patient-reported-outcomes, biochemical hypoglycemia at baseline (based on 4-week masked rtCGM use), hours per day in time in range and hyperglycemia, and use of rtCGM were used as predictors. Model fit of the block-wise regression suggests that none of the baseline characteristics did predict hypoglycemia avoidance. However, entering use of rtCGM led to a rise of Nagelkerke´s R² from 0.061 to 0.331. This indicates that rtCGM use was the most important predictor for hypoglycemia avoidance. In the CGM Group, 76.1% of the patients compared to 26.3% in the Control group could avoid hypoglycemic events (Odds ratio 9.8, 95% CI 4.2 to 23.0). This suggests that rtCGM use is effective in patients with type 1 diabetes and hypoglycemia problems regardless of diabetes duration, glycemic control, severity of hypoglycemia problems, and exposure to biochemical hypoglycemia at baseline.

DOI
URL
Peer Reviewed
yes
International Distribution
yes
Open Access Journal
no
Type
Article
URI
Activation date
2020-01-15

Permalink: https://fis.uni-bamberg.de/handle/uniba/47027 · Data as JSON · Cite: BibTeX · RIS

Data as of: 2026-11-16

Restricted read-only access: login, editing and submission are temporarily disabled.